New drug cocktail shows promise in early ovarian cancer trial

NCT ID NCT05276973

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for women with advanced ovarian cancer. The study involves 25 participants with stage III or IV disease. The goal is to find the best dose and see if the combination can better control tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ipatasertib (a targeted drug) plus paclitaxel and carboplatin (chemotherapy)
What this could lead to: If it works, this could lead to a more effective initial treatment for advanced ovarian cancer, potentially delaying tumor growth.
What could go wrong: This is a very early (Phase I) trial with only 25 participants, so it's mainly checking safety and dosing. The drug combination may not work better than standard chemo, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian cancer ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA OVARIAN ENDOMETRIOID ADENOCARCINOMA OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA STAGE III FALLOPIAN TUBE CANCER AJCC V8 STAGE III OVARIAN CANCER AJCC V8 STAGE III PRIMARY PERITONEAL CANCER AJCC V8 STAGE IV FALLOPIAN TUBE CANCER AJCC V8 STAGE IV OVARIAN CANCER AJCC V8 STAGE IV PRIMARY PERITONEAL CANCER AJCC V8 UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA UNRESECTABLE FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA UNRESECTABLE OVARIAN ENDOMETRIOID ADENOCARCINOMA UNRESECTABLE OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA UNRESECTABLE PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA UNRESECTABLE PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA

Contacts and locations

Locations

Augusta University Medical Center

Augusta, Georgia, 30912, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
UCSF Medical Center-Mission Bay

San Francisco, California, 94158, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, 23298, United States
Women and Infants Hospital

Providence, Rhode Island, 02905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.